Motoko Kanno

10PUBLICATIONS
31CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PhenomenologyHaematological tumoursOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 09, 2026
Prevalence and clinicopathologic features of mismatch repair-deficient endometrial cancer in Japanese patients younger than 50 years: a single-center prospective observational study.

Hidetaka Nomura, Akiko Abe, Atsushi Fusegi

|Mar 30, 2026
Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer.

Yusuke Toyohara, Mayu Yunokawa, Ryo Nimura

|Jan 28, 2026
Surgical Timing and Survival in Advanced High-Grade Serous Ovarian Cancer in the PARP Inhibitor Era.

Motoko Kanno, Atsushi Fusegi, Naoki Miyazaki

|Mar 28, 2025
The impact of cytoreductive surgery on outcomes in high tumor burden ovarian cancer after induction of PARP inhibitors.

Motoko Kanno, Mayu Yunokawa, Atsushi Fusegi

|Dec 06, 2024
The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.

Mayu Yunokawa, Akiko Abe, Xiaofei Wang

|May 06, 2024
Author's reply to: Revisiting the meaning of Trousseau sign and syndrome.

Motoko Kanno, Mayu Yunokawa, Atsushi Fusegi

Pageof 2

Frequent Collaborators

9 joint publications

Mayu Yunokawa

9 joint publications

Hiroyuki Kanao

7 joint publications

Atsushi Fusegi

6 joint publications

Makiko Omi